Monitoring of anti-HPIgG during Helicpbacter Pylori Eradication (CROSBI ID 82927)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Antoljak, Nataša ; Vukadinović, Marija-Vesna ; Zubčić, Ana ; Topić, Elizabeta
engleski
Monitoring of anti-HPIgG during Helicpbacter Pylori Eradication
There is no doubt that Helicobacter pylori infections results in inflammation of the gastric mucosa, called chronic superficial gastritis, which leads to peptic ulceration in some patients. Diagnostic tests are divided into two major categories: non-invasive tests and invasive methods using endoscopy. The aim of this study was to monitor anti-HP IgG by the ELISA Pyloriset EIA-G (Orion diagnostica, Finland) during triple eradication therapy. Specific IgG were measured before treatment and then two, four and six months thereafter in plasma of 34 patients with positive history of dyspeptic illnes. The mean percentage of titer decline was greatest two months after treatment (49 percent, p<0.001). A statistically significant decrease continued after 4 and 6 months (66 percent and 78 percent of titer before therapy, respectively ; p<0.005). We found 94 percent of patients to be successfully seroconverted after 6 months monitoring. Contrary to other studies, our results showed that in 12 percent of the patients seroconversion occurred only after 6 months so that for such patients we recommend monitoring for a period of six months.
Monitoring of anti-HPIgG during Helicpbacter Pylori Eradication
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano